Search Results
Aug 30, 2026, 06:15 ET Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72 weeks in participants with obesity or overweight without type 2 diabetes (AURORA-1) and with type 2 diabetes (AURORA-2).-
More news about: Ascletis Pharma Inc.
Aug 28, 2026, 07:15 ET La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
cercano. Conoce más Mounjaro es una medicina recetada en forma de pluma precargada, de una sola dosis, disponible en 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg o 15 mg por inyección de 0.5 mL. Para obtener más información, llama al 1-800-LillyRX (800-545-5979) o visita
More news about: Eli Lilly and Company
Aug 28, 2026, 07:00 ET FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
away.Learn more Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-800-LillyRX (800-545-5979) or go to
More news about: Eli Lilly and Company
Aug 28, 2026, 07:00 ET InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
received ifebemtinib (100mg once a day) plus garsorasib (600mg twice a day) orally. And in Part 2-randomized study, 36 previously-treated KRAS G12C-mutant metastatic CRC patients were enrolled and randomly assigned (1:1) to receive ifebemtinib plus garsorasib or garsorasib alone (600mg twice a day) orally.
More news about: InxMed Co., Ltd
Aug 27, 2026, 16:22 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
treatment of wet age-related macular degeneration (wet AMD)." The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals' (REGN) Eylea) was not met in the entire dataset. On this news, EyePoint's stock price fell $9.88 per share,
More news about: Pomerantz LLP
Aug 27, 2026, 12:00 ET VITURE and S-GAME Unveil Phantom Beast -- the Official Phantom Blade Zero XR Glasses
MaterialsFrame/Hinge: Mg-Al Alloy | Temple: PC + TPE
More news about: VITURE
Aug 27, 2026, 10:25 ET Lavinia Expands with Hemp Versions of Its Iconic Sexual Wellness Gummies
combines hemp-derived Delta-9 cannabinoids with a blend of botanicals including Horny Goat Weed, Longjack and Maca Root. The gummies are vegan, dosed at 5mg of THC per gummy for a customizable experience and are available in Pineapple and Watermelon flavors. Each jar contains twenty-five gummies and retails
More news about: Lavinia
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
with IO plus chemotherapy), CS2009 monotherapy (30 mg/kg dose level) yielded an ORR of 38.5% and a DCR of 84.6%; In patients with heavily pretreated metastatic colorectal cancer (mCRC), CS2009 monotherapy (30 mg/kg dose level) achieved an ORR of 20% and a DCR
More news about: CStone Pharmaceuticals
Aug 26, 2026, 14:56 ET Horticulture Co., a Leading U.S. Beverage Company focused on Hemp-Derived THC and Functional Adult Beverages, Sees Tremendous Success From 112.5% YoY Growth to Expansion into New Markets, Securement of New Retailers Including ABC Fine Wine & Spirits, Sprouts, and BP Thorntons to Celebrity Partnerships Of-Note with the Likes of NBA Legends Allen Iverson and Al Harrington
Spritz is positioned as a sleek, sexy, alcohol-alternative beverage. Current core flavors include Citrus, Strawberry and Blueberry, with both 5mg and 10mg THC offerings. The flavor and functionality include Citrus/Sativa for a bright, refreshing and uplifting profile; Strawberry/Hybrid for a fruit-forward,
More news about: Tempters
Aug 26, 2026, 10:49 ET Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
patients, 30 at 200 mg and 30 at 400 mg, who had previously received one to five prior systemic therapies for cGvHD.Key efficacy results: At 24-weeks, GV101 yielded a bORR of 86.2% (95% CI: 68.3 to 96.1) at 400 mg and 67.9% (95% CI: 47.6 to 84.1) at 200 mg; FFS was 89.4% at 400 mg and 78.6% at
More news about: Graviton BioScience Corporation
Aug 26, 2026, 10:48 ET SimuTech Group Engineers Co-Author Chapter in Open-Access Medical Device VVUQ Handbook
https://simutechgroup.zoom.us/webinar/register/5217871616350/WN_ojNrlsBkQ5GrZx36x9m2mg.The published chapter is available at
More news about: SimuTech Group Inc
Aug 26, 2026, 09:00 ET MILK BAR® PARTNERS WITH BEYOND MEAT® TO DEBUT NEW SAVORY PLANT-FORWARD OPTIONS GUESTS HAVE BEEN CRAVING
Company™, is a plant protein company offering a portfolio of plant-based products made with non-GMO ingredients, no added hormones or antibiotics, and 0mg of cholesterol per serving. Founded in 2009, Beyond Meat's core products are designed to have the same taste and texture as animal-based meat while being
More news about: Milk Bar
Aug 26, 2026, 07:00 ET HUMAN CLINICAL STUDY FINDS SOURSOP JUICE CONSUMPTION SIGNIFICANTLY LOWERS BLOOD PRESSURE AND SERUM URIC ACID
marker.Under the researchers' ACC/AHA subgroup analysis, mean serum uric acid in participants consuming soursop declined from approximately 5.74 mg/dL at baseline to 5.43 mg/dL after 12 weeks, while the control group's mean level remained higher at the end of the study.The researchers concluded that soursop
More news about: SOPREME Soursop
Aug 26, 2026, 06:45 ET Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.Learn more Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979)
More news about: Eli Lilly and Company
Aug 25, 2026, 14:49 ET Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
used in conjunction with glucose levels. The Urgent Low Glucose alarm and Urgent High Ketones alarm may not detect all instances of glucose less than 55 mg/dL and ketones higher than 3.0 mmol/L, so these should be used together with respective sensor readings for treatment decisions. Get medical attention
More news about: Abbott
Aug 25, 2026, 10:00 ET SAINT JAMES ICED TEA EXPANDS INTO YERBA MATE WITH NEW ORGANIC BEVERAGE LINE, SAINT JAMES YERBA MATE
delivers three bold flavors, 150mg of natural caffeine, and a national campaign featuring Jack Hughes, Victor Cruz, and Isabela Rangel Grutman.Saint James Iced Tea launches new certified organic beverage line, Saint James Yerba Mate, with 150mg of natural caffeine, 20-25 calories,
More news about: Saint James Iced Tea
Aug 25, 2026, 09:00 ET KHALIFA KUSH LAUNCHES THC BEVERAGES WITH DEBUT OF KHALIFA KUSH & ORANGE JUICE
moment that helped define a generation of cannabis culture, and that continues to resonate with fans more than a decade later. Available in both 5mg and 10mg hemp-derived THC formulations, Khalifa Kush & Orange Juice delivers a smooth, social-ready beverage experience rooted in the quality, authenticity,
More news about: Khalifa Kush
Aug 25, 2026, 09:00 ET Hivemind Digital Group Announces $17 Million Strategic Funding Round Led by M&G Investments
multimedia:https://www.prnewswire.com/news-releases/hivemind-digital-group-announces-17-million-strategic-funding-round-led-by-mg-investments-302858649.htmlSOURCE
More news about: Hivemind
Aug 25, 2026, 08:13 ET PLT Health Solutions Brings Its Clinically Supported Branded Ingredient Platform to Vitafoods Asia
preservation and is now found in consumer brands in Asia and around the world. A 2025 study on Dynagenix® Muscle+Joint Formula showed that just 40 mg/day led to statistically significant improvements in joint comfort, stiffness, and function as early as 5 days after initial supplementation. Neutral-tasting
More news about: PLT Health Solutions
Aug 25, 2026, 08:00 ET CivicaScript® launches 3 low-cost generics to expand its market impact
Yulithira™ (everolimus) tablets, 2.5 mg, 5 mg, 7.5 mg and 10 mg, used to treat hormone receptor-positive, HER2-negative breast cancer; neuroendocrine tumors; renal cell carcinoma; tuberous sclerosis complex
More news about: Civica Rx
Aug 25, 2026, 07:00 ET Joy Organics Expands Organic THC-Free CBD Gummy Line With New 50mg Strength and Sour Apple Flavor
collection with a new 50mg strength and the introduction of sour apple, a brand-new flavor. The new gummies contain 50mg of broad spectrum CBD per serving, offering customers a higher-strength option alongside Joy Organics' existing THC-free CBD gummy formulations. The 50mg strength is available
More news about: Joy Organics
Aug 25, 2026, 07:00 ET Basking Biosciences Announces Positive Topline Phase 1 Data for BB-025, the Reversal Agent for its Acute Ischemic Stroke Thrombolytic Therapy BB-031
60 healthy adult subjects enrolled in the study received a single administration of BB-025 at doses up to 12 mg/kg, either alone or following a single dose of BB-031, at doses up to 6 mg/kg. When administered following a single dose of BB-031, BB-025 produced a complete, rapid, and stable reversal of
More news about: Basking Biosciences Inc.
Aug 24, 2026, 19:12 ET FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
IMAAVY and discuss any questions you have with your doctor.Dosage Form and Strengths: IMAAVY is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.ABOUT JOHNSON & JOHNSONAt Johnson & Johnson, we
More news about: Johnson & Johnson
Aug 24, 2026, 08:43 ET Leqembi Iqlik® for initiation treatment launched in the US
introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500 mg once weekly, delivered as two 250 mg injections, each administered in approximately 15 seconds.Expanding convenience and flexibility in Alzheimer's careThe
More news about: BioArctic
Aug 24, 2026, 08:39 ET Leqembi Iqlik® for initiation treatment launched in the US
introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500 mg once weekly, delivered as two 250 mg injections, each administered in approximately 15 seconds.Expanding convenience and flexibility in Alzheimer's careThe
More news about: BioArctic